Table 2 Demographic and biomarker information of the BioFINDER-2 cohort by clinical and biomarker-defined groups
CU- (n = 236) | CU + (n = 73) | MCI- (n = 44) | MCI + (n = 68) | AD (n = 81) | Non-AD- (n = 33) | Non-AD + (n = 28) | P-value | |
|---|---|---|---|---|---|---|---|---|
Age, years | 60.8 (14.9) | 70.7 (8.2) | 68.7 (8.0) | 72.4 (7.4) | 73.5 (7.2) | 72.6 (8.2) | 74.7 (6.0) | < 0.0001* |
Female, n (%) | 118 (50) | 31 (43) | 15 (34) | 35 (52) | 41 (51) | 9 (27) | 10 (36) | 0.074 |
Education, years a | 12.7 (3.1) | 12.3 (3.8) | 12.2 (3.6) | 12.4 (4.1) | 11.8 (3.9) | 10.6 (3.4) | 13.8 (4.0) | 0.008* |
APOE-ε4 carriers, n (%) b | 84 (35.6) | 50 (68.5) | 10 (22.7) | 48 (70.6) | 54 (66.7) | 5 (15.2) | 17 (60.7) | < 0.0001* |
MMSE | 28.7 (1.8) | 28.6 (1.8) | 27.5 (1.9) | 26.7 (1.9) | 19.8 (4.7) | 22.7 (3.7) | 21.8 (5.6) | < 0.0001* |
Aß PET (SUVR) | 0.62 (0.04) | 0.84 (0.19) | 0.63 (0.05) | 0.98 (0.19) | 1.08 (0.18) | 0.63 (0.03) | - | < 0.0001* |
Tau PET (SUVR) | 1.13 (0.10) | 1.29 (0.34) | 1.16 (0.09) | 1.44 (0.43) | 2.12 (0.65) | 1.18 (0.16) | 1.31 (0.21) | < 0.0001* |
p-Tau181 (fmol/mL) | 0.94 (0.33) | 1.13 (0.45) | 0.97 (0.27) | 1.49 (0.58) | 1.76 (0.77) | 1.07 (0.52) | 1.17 (0.34) | < 0.0001* |
p-Tau199 (fmol/mL) | 0.20 (0.09) | 0.26 (0.10) | 0.23 (0.10) | 0.30 (0.12) | 0.39 (0.16) | 0.25 (0.11) | 0.26 (0.08) | < 0.0001* |
p-Tau202 (fmol/mL) | 0.06 (0.03) | 0.08 (0.05) | 0.07 (0.04) | 0.08 (0.03) | 0.10 (0.04) | 0.06 (0.03) | 0.07 (0.03) | < 0.0001* |
p-Tau205 (fmol/mL) | 0.02 (0.03) | 0.04 (0.04) | 0.02 (0.02) | 0.05 (0.04) | 0.09 (0.06) | 0.02 (0.02) | 0.03 (0.02) | < 0.001* |
p-Tau217 (fmol/mL) | 0.06 (0.04) | 0.21 (0.17) | 0.08 (0.06) | 0.31 (0.22) | 0.57 (0.32) | 0.10 (0.09) | 0.18 (0.08) | < 0.0001* |
p-Tau231 (fmol/mL) | 0.02 (0.03) | 0.07 (0.11) | 0.02 (0.02) | 0.10 (0.14) | 0.20 (0.28) | 0.04 (0.05) | 0.04 (0.05) | < 0.0001* |
p-Tau396 (fmol/mL) | 0.06 (0.11) | 0.07 (0.06) | 0.05 (0.04) | 0.09 (0.10) | 0.08 (0.06) | 0.05 (0.04) | 0.04 (0.02) | 0.038* |